Patents by Inventor Makoto Ikeya
Makoto Ikeya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11959100Abstract: As a technique for proliferating neural crest cells without reducing differentiation capacity, provided is a method for producing neural crest cells, comprising the steps of: (1) obtaining neural crest cells; and (2) suspension-culturing the neural crest cells in a medium comprising a GSK3? inhibitor and a basic fibroblast growth factor (bFGF), wherein the medium comprises the GSK3? inhibitor with a concentration that exhibits an effect equivalent to that exhibited by CHIR99021 with a concentration of higher than 1 ?M and lower than 5 ?M.Type: GrantFiled: November 29, 2018Date of Patent: April 16, 2024Assignees: Kyoto University, Takeda Pharmaceutical Company LimitedInventors: Makoto Ikeya, Yayoi Kamiya
-
Publication number: 20220313733Abstract: A method for producing renal stromal cells, comprising a step (3) of culturing renal stromal precursors in a medium comprising a platelet derived growth factor receptor agonist to obtain renal stromal cells is provided as a technique for supplying renal stromal cells. This production method can further comprise a step (2) of inducing renal stromal precursors from neural crest cells, and a step (1) of culturing pluripotent stem cells in a medium comprising a GSK3? inhibitor, a TGF? inhibitor, and retinoic acid and/or a derivative thereof to induce neural crest cells.Type: ApplicationFiled: June 10, 2020Publication date: October 6, 2022Applicants: Kyoto University, Takeda Pharmaceutical Company LimitedInventors: Makoto IKEYA, Daisuke KAMIYA
-
Patent number: 11207303Abstract: The present invention relates to a prophylactic or therapeutic agent for fibrodysplasia ossificans progressiva comprising as an active ingredient, at least one compound selected from the group consisting of rapamycin, temsirolimus, everolimus, ridaforolimus, TAFA93, umirolimus, olcorolimus, zotarolimus, and pharmaceutically acceptable salts thereof.Type: GrantFiled: January 25, 2016Date of Patent: December 28, 2021Assignees: Kyoto University, Sumitomo Dainippon Pharma Co., Ltd.Inventors: Junya Toguchida, Makoto Ikeya, Akira Ohta, Kyosuke Hino
-
Publication number: 20210363485Abstract: Provided is a method of producing a somite cell from a pluripotent stem cell, comprising the step of culturing a pluripotent stem cell in a medium comprising a GSK3? inhibitor. Provided is a method of producing a dermatome cell from a somite cell, comprising the step of culturing a somite cell in a medium comprising a GSK3? inhibitor and BMP. Provided is a method of producing a syndetome cell from a sclerotome cell, comprising the steps of culturing a sclerotome cell in a medium comprising FGF and then culturing the cell in a medium comprising BMP and TGF?. Provided is a method of producing a mesenchymal stromal cell from a somite cell, comprising the step of culturing a somite cell in a medium comprising FGF. Provided are methods of producing a myotome cell, a dermatome cell, a sclerotome cell, and a syndetome cell from a pluripotent stem cell through a somite cell by appropriately combining the above methods and known methods.Type: ApplicationFiled: March 14, 2019Publication date: November 25, 2021Inventors: Makoto IKEYA, Taiki NAKAJIMA
-
Publication number: 20210198624Abstract: A method for producing enteric neural precursors, comprising the steps of: (1) providing enteric neural precursors; and (2) culturing the enteric neural precursors in a medium comprising an ERBB3 agonist and/or an ERBB4 agonist is provided as a technique for allowing enteric neural precursors to proliferate by culture while maintaining their differentiation capacity into enteric nerve cells and glial cells.Type: ApplicationFiled: August 21, 2019Publication date: July 1, 2021Inventors: Makoto Ikeya, Yayoi Kamiya, Daisuke Kamiya, Teruyoshi Yamashita, Kazumi Take
-
Patent number: 10947508Abstract: Mesenchymal stem cells may be culture for a long period, without using any special apparatus, equipment and the like, in a medium in which seven kinds of nonessential amino acids of glycine, alanine, serine, proline, asparagine, aspartic acid, and glutamic acid are reduced.Type: GrantFiled: February 17, 2017Date of Patent: March 16, 2021Assignees: AJINOMOTO CO., INC., Kyoto UniversityInventors: Yonghui Jin, Ikue Harata, Sho Senda, Hiroki Ozawa, Tsuyoshi Kobayashi, Junya Toguchida, Makoto Ikeya
-
Publication number: 20210002608Abstract: As a technique for proliferating neural crest cells without reducing differentiation capacity, provided is a method for producing neural crest cells, comprising the steps of: (1) obtaining neural crest cells; and (2) suspension-culturing the neural crest cells in a medium comprising a GSK3? inhibitor and a basic fibroblast growth factor (bFGF), wherein the medium comprises the GSK3? inhibitor with a concentration that exhibits an effect equivalent to that exhibited by CHIR99021 with a concentration of higher than 1 ?M and lower than 5 ?M.Type: ApplicationFiled: November 29, 2018Publication date: January 7, 2021Inventors: Makoto Ikeya, Yayoi Kamiya
-
Patent number: 10260068Abstract: The invention provides a prophylactic agent or therapeutic agent for fibrodysplasia ossificans progressiva, containing as an active ingredient a binding inhibitor that inhibits interaction between activin and activin A receptor type I (ACVR1), or an expression suppressor that suppresses expression of activin.Type: GrantFiled: March 30, 2015Date of Patent: April 16, 2019Assignees: Sumitomo Dainippon Pharma Co., Ltd., Kyoto UniversityInventors: Kyosuke Hino, Junya Toguchida, Makoto Ikeya
-
Publication number: 20180353485Abstract: The present invention relates to a prophylactic or therapeutic agent for fibrodysplasia ossificans progressiva comprising as an active ingredient, at least one compound selected from the group consisting of rapamycin, temsirolimus, everolimus, ridaforolimus, TAFA93, umirolimus, olcorolimus, zotarolimus, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: January 25, 2016Publication date: December 13, 2018Applicants: Kyoto University, Sumitomo Dainippon Pharma Co., Ltd.Inventors: Junya Toguchida, Makoto Ikeya, Akira Ohta, Kyosuke Hino
-
Patent number: 9921212Abstract: A method of screening for a therapeutic and/or preventive drug for cartilaginous hyperplasia and a therapeutic and/or preventive drug for cartilaginous hyperplasia are provided. The following are provided: a method of screening for a therapeutic and/or preventive drug for cartilaginous hyperplasia, comprising a step of culturing chondroprogenitor cells under conditions in which the cells are brought into contact with a test substance and conditions in which the cells are not brought into contact with the test substance and a step of determining the SOX9 promoter activity, cAMP level, or degree of phosphorylation of CREB in the cells or the extracellular matrix volume in a culture; and a therapeutic and/or preventive drug for cartilaginous hyperplasia, comprising as an active ingredient an adenylate cyclase inhibitor.Type: GrantFiled: October 9, 2015Date of Patent: March 20, 2018Assignee: Kyoto UniversityInventors: Junya Toguchida, Ryuta Nishikomori, Koji Yokoyama, Makoto Ikeya, Toshio Heike
-
Patent number: 9862929Abstract: The present invention provides a method of producing a skeletal muscle cell from a pluripotent stem cell, which includes a step of expressing one or more exogenous factors selected from MyoD, Myf5 and nucleic acids encoding them on a pluripotent stem cell.Type: GrantFiled: August 17, 2012Date of Patent: January 9, 2018Assignee: Kyoto UniversityInventors: Hidetoshi Sakurai, Akihito Tanaka, Knut Woltjen, Makoto Ikeya
-
Publication number: 20170211070Abstract: The invention provides a prophylactic agent or therapeutic agent for fibrodysplasia ossificans progressiva, containing as an active ingredient a binding inhibitor that inhibits interaction between activin and activin A receptor type I (ACVR1), or an expression suppressor that suppresses expression of activin.Type: ApplicationFiled: March 30, 2015Publication date: July 27, 2017Applicants: Sumitomo Dainippon Pharma Co., Ltd., Kyoto UniversityInventors: Kyosuke Hino, Junya Toguchida, Makoto Ikeya
-
Publication number: 20170198258Abstract: Mesenchymal stem cells may be culture for a long period, without using any special apparatus, equipment and the like, in a medium in which seven kinds of nonessential amino acids of glycine, alanine, serine, proline, asparagine, aspartic acid, and glutamic acid are reduced.Type: ApplicationFiled: February 17, 2017Publication date: July 13, 2017Applicants: AJINOMOTO CO., INC., Kyoto UniversityInventors: Yonghui JIN, lkue HARATA, Sho SENDA, Hiroki OZAWA, Tsuyoshi KOBAYASHI, Junya TOGUCHIDA, Makoto IKEYA
-
Publication number: 20160177406Abstract: A method of screening for a therapeutic and/or preventive drug for cartilaginous hyperplasia and a therapeutic and/or preventive drug for cartilaginous hyperplasia are provided. The following are provided: a method of screening for a therapeutic and/or preventive drug for cartilaginous hyperplasia, comprising a step of culturing chondroprogenitor cells under conditions in which the cells are brought into contact with a test substance and conditions in which the cells are not brought into contact with the test substance and a step of determining the SOX9 promoter activity, cAMP level, or degree of phosphorylation of CREB in the cells or the extracellular matrix volume in a culture; and a therapeutic and/or preventive drug for cartilaginous hyperplasia, comprising as an active ingredient an adenylate cyclase inhibitor.Type: ApplicationFiled: October 9, 2015Publication date: June 23, 2016Applicant: KYOTO UNIVERSITYInventors: Junya Toguchida, Ryuta Nishikomori, Koji Yokoyama, Makoto Ikeya, Toshio Heike
-
Publication number: 20140370537Abstract: The present invention provides a method of producing a skeletal muscle cell from a pluripotent stem cell, which includes a step of expressing one or more exogenous factors selected from MyoD, Myf5 and nucleic acids encoding them on a pluripotent stem cell.Type: ApplicationFiled: August 17, 2012Publication date: December 18, 2014Applicant: KYOTO UNIVERSTIYInventors: Hidetoshi Sakurai, Akihito Tanaka, Knut Woltjen, Makoto Ikeya